North America’s BEST Small Cap Stock Ideas
On Thursday, Acme United Corporation (ACU – $8.40) announced that net sales for the third quarter ended September 30, 2009 were $15.3 million compared to $19.2 million in the comparable period of 2008, a decrease of 20% (19% local currency). Contributing to the decline was an unexpected order of approximately $1.2 million from a major retailer in the third quarter […]
Read moreThe five stocks that we recommended in 2009 have done very well so far. At today’s closing prices, our five recommendations: Hemispherx Biopharma (HEB), Orsus Xelent (ORS), Boots & Coots (WEL), Acme United (ACU) and Global Green Solutions (GGRN) are up between 30 and 370 percent, or +127% on average. Obviously, it’s impossible to predict if our following recommendations will […]
Read moreOn Wednesday, Acme United Corporation (ACU – $10.00) announced excellent news when its Board of Directors approved a new stock repurchase program of up to 200,000 common shares. This new program goes on top of 49,335 shares that may still be repurchased under its previous program, which was announced in December of 2008. To get this in perspective, 249,335 shares […]
Read moreThe Bakersfield Californian, one of California’s leading newspapers, published a very interesting article about two multimillion-dollar renewable energy projects being developed in Kern County, California, USA. One of these projects is the Global Green Solutions’ (GGRN – $0.14) Greensteam project at Aera Energy, one of California’s largest oil and gas producers. If you haven’t read the article yet, we strongly […]
Read moreIt’s very unfortunate Dr. Hasegawa wasn’t able to attend the Annual Conference of the Japanese Society For Vaccinology held in Sapporo, Japan on September 27, 2009. Although an abstract was published on the Hemispherx website, we feel as if the investment community only glanced over the presentation. To help us clarify the abstract, we had a conference call this week […]
Read moreWe also received positive news from our biotech stock Hemispherx Biopharma (HEB – $2.05). The Company will spend up to $4.4 million for engineering studies, capital improvements, system upgrades, and introduction of building management systems to enhance production for Alferon N and its two experimental therapeutics Alferon LDO and Ampligen. These investments will bring the capacity of Hemispherx’ manufacturing site […]
Read moreFurthermore Boots & Coots (WEL – $1.68) announced it acquired the external abrasive jet cutting systems from Halliburton Company. The abrasive jet cutting system was developed by Halliburton in 1991 to assist firefighting crews in Kuwait battle more than seven hundred fires left after the Iraq invasion. The external abrasive jet cutter is designed to be easily positioned on a […]
Read moreHemispherx Biopharma (HEB – $2.03) announced on Wednesday it cancelled its adjourned stockholders’ meeting. The reason was very simple, the Company obtained insufficient votes to pass proposal no. 3. With this proposal being the sole purpose of the adjourned stockholders’ meeting, there was no need to hold the meeting. In proposal 3, shareholders were asked if HEB could increase the […]
Read moreAlthough Acme United’s sales and earnings were impacted by the economic downturn in the second quarter, it’s encouraging to note that while net sales in the U.S. segment decreased 17% compared to the same period in 2008, sales in Canada only declined approximately 1% in local currency (down 12% in U.S. dollars) and even increased 11% in Europe in local […]
Read moreMany thanks to everybody who responded by e-mail or on our blog to last week’s appeal: “Do you have an idea why Orsus Xelent (ORS – $0.72) is trading at such a low P/E?”. Most answers were unanimous and something like: management (CEO, CFO and several members of the board) and the Company’s auditor has changed during the last few […]
Read more